MR spectroscopy in monitoring the treatment of Wilson's disease patients

Movement Disorders

Volumn 23, Issue 11, 2008, Pages 1560-1566

  Tarnacka, Beata ^a   Szeszkowski, Wojciech ^b   Golebiowski, Marek ^b   Czlonkowska, Anna ^a,b  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Magnetic resonance spectroscopy; Monitoring; Wilson's disease

Indexed keywords

CHOLINE; CREATININE; GLUTAMINE; INOSITOL; LIPID; N ACETYLASPARTIC ACID; PENICILLAMINE; ZINC SULFATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; GLOBUS PALLIDUS; HUMAN; LIVER FAILURE; LOW DRUG DOSE; MALE; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY ANALYSIS; WILSON DISEASE;

ADOLESCENT; ADULT; ANTIDOTES; ASPARTIC ACID; BRAIN; CASE-CONTROL STUDIES; CHOLINE; CREATINE; FEMALE; FOLLOW-UP STUDIES; GLUTAMIC ACID; HEPATOLENTICULAR DEGENERATION; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PENICILLAMINE; PROTONS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 53149113795     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22163     Document Type: Article

References (22)

1. Hoogenraad T. Wilson's disease. London: WB Saunders; 1997. p 14-24, 72-73.
2. Czlonkowska A, Tarnacka B, Litwin T, Gajda J, Rodo M. Wilson's disease - cause of mortality in 164 patients during 1992-2003 observation period. J Neurol 2005;252:698-703.
3. Magalhaes A, Caramelli P, Menezes J. Wilson's disease: MRI with clinical correlation. Neuroradiology 1994;36:97-100.
4. Nazer H, Brismar J, Al-Kawi M, Gunasekaran T, Jurulf KH. Magnetic resonance imaging of the brain in Wilson's disease. Neuroradiology 1993;35:130-133.
5. Rudkin T, Arnold D. Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders. Arch Neurol 1999;56:919-926.
6. Danielsen E, Ross B. Magnetic resonance spectroscopy diagnosis of neurological diseases. New York: Marcel Dekker; 1999. p 1-43.
7. Adamson A, Rand S, Prost R. Focal brain lesions: effect of single-voxel proton MR spectroscopic findings on treatment decisions. Radiology 1998;209:73-78.
8. Czlonkowska A, Galewicz A, Rodo M, Wehr H. Observation on copper metabolism in Wilson's disease. Acta Univ Carol Med 1973;56:175-178.
9. Marcus C, Sargentoni J, Bryant D, Taylor-Robinson S. H MRS in patients with chronic hepatic encephalopathy: regional variations. In: Proceedings of the Society of Magnetic Resonance, Society of Magnetic Resonance, Berkeley, CA, 1994, Vol. 2, p 571 (abstract).
10. Bottomley P. Spatial localization in NMR spectroscopy in vivo. Ann NY Acad Sci 1986;508:333-348.
11. Alanen A, Komu M, Pentinen M, Leino R. Magnetic resonance imaging and proton MR spectroscopy in Wilson's disease. Br J Radiol 1999;72:749-756.
12. Page R, Davie F, MacManus D, et al. Clinical correlation of brain MRI and MRS abnormalities in patients with Wilson's disease. Neurology 2004;63:638-643.
13. Lucato LT, Barbosa M, Machado A, et al. Proton MR spectroscopy in Wilson disease: analysis of 36 cases. Am J Neuroradiol 2005;26:1066-1071.
14. Cendes F, Andermann Dubeau F, Matthews P, Arnold D. Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy. Evidence from proton MR spectroscopic imaging. Neurology 1997;49:1525-1533.
15. Kim H, Kim D, Lee B, Jeong B, Choi C, Lee J. Diffusion-weighted image and MR spectroscopic analysis of a case of MELAS with repeated attacks. Yonsei Med J 2001;42:128-133.
16. Naranyanan S, De Stefano N, Francis G, et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001;248:979-986.
17. Bates T, Strangward M, Keelan J. Inhibition of N-acetylaspartate production: implications for 1 H-MRS studies in vivo. Neuroreport 1996;7:1397-1400.
18. Dauntry C, Vaufrey F, Brouillet E, Bizat N, Henry P, Conde F. Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial t oxin 3-nitropropionic acid. J Cereb Blood Flow Metab 2000;20:789-799.
19. Aricello M, Rotillo G, Rossi L. Copper-dependent toxicity in SH-SY5Y neuroblastoma cells involves mitochondrial damage. Biochem Biophys Res Commun 2005;327:454-459.
20. Kreis R, Farrow N, Ross B. Diagnosis of hepatic encephalopathy by proton magnetic resonance spectroscopy. Lancet 1990;336: 635-636.
21. Pujol J, Kulisevsky J, Moreno A, et al. Neurospectroscopic alterations and globus pallidus hyperintensity as related magnetic resonance markers of reversible hepatic encephalopathy. Neurology 1996;47:1526-1530.
22. Ross B, Jacobson S, Villami F, et al. Subclinical hepatic encephalopathy: proton MR spectroscopic abnormalities. Radiology 1994;193:457-463.